NEW YORK, April 10, 2017 /PRNewswire/ --
Companies in the Drug Manufacturers space manufacture and process pharmaceutical products. Large companies benefit from their
economies of scale in research, manufacturing, and marketing. Today, Stock-Callers.com takes a closer look at four major industry
players: Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), and AbbVie Inc. (NYSE:
ABBV). Learn more about these stocks by downloading their comprehensive and free reports at:
http://stock-callers.com/registration
Pfizer
New York headquartered Pfizer Inc.'s shares finished Friday's session 0.03% lower at
$34.10. A total volume of 13.95 million shares was traded. The stock has gained 0.15% in the last
month, 2.89% over the previous three months, and 6.06% on an YTD basis. The Company's shares are trading above their 50-day and
200-day moving averages by 1.72% and 2.89%, respectively. Moreover, shares of Pfizer, which discovers, develops, manufactures,
and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 53.80.
On March 31 st, 2017, Pfizer announced that the US Food FDA has approved a
supplemental New Drug Application for its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor,
IBRANCE® (palbociclib), based on the results from the confirmatory Phase 3 trial PALOMA-2. The FDA action converts the
accelerated approval of IBRANCE to regular approval, and broadens the range of anti-hormonal therapy that may be administered
with IBRANCE. PFE complete research report is just a click away and free at:
http://stock-callers.com/registration/?symbol=PFE
Merck
Shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. ended the day 0.17% lower
at $63.13 with a total trading volume of 7.71 million shares. The stock has advanced 5.50% in the
previous three months and 8.01% since the start of this year. The Company's shares are trading 3.34% above their 200-day moving
average. Moreover, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 38.79.
On April 07 th, 2017, Merck & Co. announced that the US FDA has issued a Complete
Response Letter regarding the Company's Supplemental New Drug Applications for JANUVIA® (sitagliptin),
JANUMET® (sitagliptin and metformin HCl), and JANUMET XR® (sitagliptin and metformin HCl extended-release). With these
applications, Merck is seeking to include data from TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) in the
prescribing information of sitagliptin-containing medicines. The complimentary report on MRK can be downloaded at:
http://stock-callers.com/registration/?symbol=MRK
Johnson & Johnson
New Brunswick, New Jersey-based Johnson & Johnson's stock declined 0.10%, closing the
session at $124.92. A total volume of 3.61 million shares was traded. The Company's shares have
gained 8.12% in the previous three months and 9.15% on an YTD basis. The stock is trading 3.19% above its 50-day moving average
and 6.22% above its 200-day moving average. Additionally, shares of Johnson & Johnson, which together with its subsidiaries,
researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 59.44.
On March 21 st, 2017, Johnson & Johnson announced that it will host a conference
call for investors at 8:30 a.m. ET on Tuesday, April 18
th, 2017, to review first-quarter results. Dominic Caruso, Vice President,
Finance and CFO, and Joseph J. Wolk, Vice President, Investor Relations, will host the call. The
webcast is accessible on the Company's website. Sign up for your complimentary research report on JNJ at:
http://stock-callers.com/registration/?symbol=JNJ
AbbVie
On Friday, shares in North Chicago, Illinois-based AbbVie Inc. finished the session 0.71%
higher at $65.54. A total volume of 5.41 million shares was traded. The stock has gained 1.61% in
the last month, 3.78% over the previous three months, and 5.72% on an YTD basis. The Company's shares are trading above their
50-day and 200-day moving averages by 3.60% and 5.45%, respectively. Furthermore, shares of AbbVie, which discovers, develops,
manufactures, and sells pharmaceutical products worldwide, have an RSI of 61.31.
On March 22 nd, 2017, research firm Societe Generale upgraded the Company's stock
rating from 'Sell' to 'Hold'.
On April 07 th, 2017, AbbVie announced detailed results from a Phase-2b clinical
trial evaluating the efficacy and safety of elagolix alone or in combination with add-back therapy (estradiol/norethindrone
acetate) compared to placebo. The data demonstrated that elagolix, with and without add-back therapy, met the primary
efficacy endpoint of reduced heavy menstrual bleeding as compared to placebo. Get free access to your research report on ABBV
at:
http://stock-callers.com/registration/?symbol=ABBV
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES :
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you ' re
a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between
09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA